SCHEMBL30712086

SCHEMBL30712086

CCNC(=O)C(=O)c1c[nH]c2ccc(F)c(O)c12

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ GABRP O00591 8/20 0.43
▸ GABRD O14764 8/20 0.43
▸ GABRA1 P14867 8/20 0.43
▸ GABRB1 P18505 8/20 0.43
▸ GABRG2 P18507 8/20 0.43
▸ GABRB3 P28472 8/20 0.43
▸ GABRA5 P31644 8/20 0.43
▸ GABRA3 P34903 8/20 0.43
▸ GABRA2 P47869 8/20 0.43
▸ GABRB2 P47870 8/20 0.43
▸ GABRA4 P48169 8/20 0.43
▸ GABRE P78334 8/20 0.43
▸ GABRA6 Q16445 8/20 0.43
▸ GABRG1 Q8N1C3 8/20 0.43
▸ GABRG3 Q99928 8/20 0.43
▸ GABRQ Q9UN88 8/20 0.43
▸ TSHR P16473 1/20 0.39
▸ ALOX5 P09917 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31708196 0.90 NPC1 (0.43) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL31708151 0.85 IGF1R (0.38) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL31708084 0.82 — —
SCHEMBL30712098 0.79 HTR1D (0.39) —
SCHEMBL30712082 0.73 MTNR1A (0.53) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL30712083 0.73 MTNR1A (0.53) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL31708181 0.73 ALOX5 (0.39) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL12596191 0.72 GPR84 (0.50) TSHR
SCHEMBL30276861 0.71 ALOX5 (0.44) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL30712070 0.71 GABRP (0.72) GABRPGABRDGABRA1GABRB1GABRG2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4635492-A2 TRYPTAMINES AND METHODS OF TREATING MOOD DISORDERS Gilgamesh Pharmaceuticals, Inc. (US) 2025-10-22 — — EP disclosed
EP-4551212-A2 TRYPTAMINES AND METHODS OF TREATING MOOD DISORDERS Gilgamesh Pharmaceuticals, Inc. (US) 2025-05-14 — — EP disclosed
WO-2024035757-A2 TRYPTAMINES AND METHODS OF TREATING MOOD DISORDERS GILGAMESH PHARMACEUTICALS, INC. (US) 2024-02-15 — — WO disclosed
Send feedback